Equities analysts expect Strongbridge Biopharma plc (NASDAQ:SBBP) to report sales of $5.06 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Strongbridge Biopharma’s earnings, with the highest sales estimate coming in at $5.78 million and the lowest estimate coming in at $4.60 million. Strongbridge Biopharma reported sales of $5.35 million in the same quarter last year, which would suggest a negative year over year growth rate of 5.4%. The company is expected to report its next earnings report on Wednesday, October 30th.
On average, analysts expect that Strongbridge Biopharma will report full-year sales of $20.45 million for the current year, with estimates ranging from $19.98 million to $21.14 million. For the next fiscal year, analysts expect that the firm will report sales of $32.06 million, with estimates ranging from $24.38 million to $46.57 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Strongbridge Biopharma.
Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.01. Strongbridge Biopharma had a net margin of 181.52% and a return on equity of 49.92%. The firm had revenue of $6.08 million for the quarter, compared to analyst estimates of $4.82 million.
Several institutional investors and hedge funds have recently bought and sold shares of the company. River & Mercantile Asset Management LLP acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $1,445,000. Susquehanna International Group LLP acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $261,000. Jane Street Group LLC acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $257,000. D. E. Shaw & Co. Inc. boosted its stake in shares of Strongbridge Biopharma by 25.5% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 950,081 shares of the biotechnology company’s stock valued at $2,973,000 after purchasing an additional 192,760 shares in the last quarter. Finally, Vanguard Group Inc. acquired a new stake in shares of Strongbridge Biopharma in the 2nd quarter valued at approximately $257,000. Institutional investors own 52.25% of the company’s stock.
SBBP stock opened at $2.15 on Friday. Strongbridge Biopharma has a 12 month low of $2.07 and a 12 month high of $6.52. The firm has a market cap of $120.30 million, a P/E ratio of 6.94 and a beta of 0.81. The company’s 50-day moving average price is $2.57 and its two-hundred day moving average price is $3.24.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.
Featured Story: Operating Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.